Comparative performance of biomarker-based and biomarker-free HFA-ICOS models for predicting anthracycline-related cardiotoxicity

Clicks: 1
ID: 323318
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #135 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Cardio-oncology patients face an increased risk of chemotherapy-related cardiotoxicity (CTRCD). The Heart Failure Association (HFA)/International Cardio-Oncology Society (ICOS) score is a validated tool for cardiovascular (CV) risk stratification. Although cardiac biomarkers play a key role in CTRCD risk assessment and diagnosis, their availability in routine clinical practice remains limited. Purpose We aimed to compare the performance of the full HFA-ICOS model, incorporating cardiac biomarkers, with biomarker-free models, including a simplified clinical model and a modified model integrating baseline global longitudinal strain (GLS), in anthracycline-treated patients. Methods We retrospectively analyzed 316 patients treated with anthracyclines across three centers. Baseline CV risk was assessed using the HFA-ICOS score. Three models were evaluated: (1) the full HFA-ICOS model including cardiac biomarkers (troponin and NT-proBNP), (2) the mini-HFA-ICOS model excluding biomarkers, and (3) a modified biomarker-free HFA-ICOS model including baseline GLS. CTRCD was defined according to the 2022 ESC guidelines. Discriminative performance was assessed using recever operating characteristic (ROC) curves, and comparisons between models were performed using DeLong’s test. Risk reclassification analyses were also conducted. Results Asymptomatic (27%, 39%, 46%, and 60%; p 0.017) and symptomatic CTRCD (1.3%, 4.6%, 13%, and 40%; p < 0.001) were more frequent in higher risk groups. For all CTRCD definitions, the full HFA-ICOS model showed higher discrimination than the mini model (AUC 0.640 vs 0.604; p = 0.004). When baseline GLS was incorporated into the biomarker-free model, discrimination was numerically improved compared with the mini model (AUC 0.643 vs 0.604; p = 0.0004) and was comparable to the full HFA-ICOS model (AUC 0.643 vs 0.640; p = 0.75), although differences in AUC did not reach statistical significance. When excluding mild asymptomatic CTRCD to minimize biomarker-related circularity, the modified biomarker-free HFA-ICOS model including GLS demonstrated discrimination comparable to the full and mini models (AUC 0.622 vs 0.617; p = 0.87; AUC 0.622 vs 0.605; p = 0.39). Compared with the full HFA-ICOS model, the mini model resulted in risk reclassification in 7.6% of patients, entirely driven by downgrading, whereas inclusion of GLS reduced discordance with the full model (5.1%) and reclassified 3.8% of patients compared with the mini model. Conclusions While integration of cardiac biomarkers improves CTRCD risk stratification within the HFA-ICOS framework, baseline GLS provides meaningful incremental value when biomarkers are unavailable or when biomarker-independent CTRCD definitions are applied. GLS may therefore represent a pragmatic alternative to biomarkers for refining cardiotoxicity risk assessment in routine cardio-oncology practice.
Reference Key
openalex_W7172338186 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors C Madaudo, A Cannata, M Camilli, D Di Lisi, D Scelfo, A R Galassi, G Novo
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.092
URL
https://doi.org/10.1093/eurheartjsupp/suag097.092
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.